168 related articles for article (PubMed ID: 16995421)
1. [Auto- and alloreactivity of T lymphocytes in myelodysplastic syndrome].
Cukrová V; Neuwirtová R; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
Cas Lek Cesk; 2006; 145(8):647-52; discussion 653. PubMed ID: 16995421
[TBL] [Abstract][Full Text] [Related]
2. Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome.
Cukrová V; Neuwirtová R; Dolezalová L; Belicková M; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
Exp Hematol; 2009 Mar; 37(3):386-94. PubMed ID: 19136196
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome.
Pülhorn H; Herrmann M; Harms H; Jung A; Baumann I
Histopathology; 2012 Aug; 61(2):200-11. PubMed ID: 22690734
[TBL] [Abstract][Full Text] [Related]
4. Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile.
Ma L; Ceuppens J; Kasran A; Delforge M; Boogaerts M; Vandenberghe P
Leuk Res; 2007 Oct; 31(10):1373-82. PubMed ID: 17188353
[TBL] [Abstract][Full Text] [Related]
5. [Abnormal polarization of T lymphocyte induces negative hematopoietic regulation in myelodysplastic syndromes].
Wu LY; Li X; Chang CK; Ying SX; Pu Q
Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):549-54. PubMed ID: 18078133
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of regulatory T cells in patients with myelodysplastic syndrome.
Hamdi W; Ogawara H; Handa H; Tsukamoto N; Nojima Y; Murakami H
Eur J Haematol; 2009 Mar; 82(3):201-7. PubMed ID: 19018862
[TBL] [Abstract][Full Text] [Related]
8. [Immunosuppressive treatment of the myelodysplastic syndrome].
Larsen MS; Hasselbalch HC
Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
[TBL] [Abstract][Full Text] [Related]
9. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome.
Wu L; Li X; Chang C; Ying S; He Q; Pu Q
Int J Lab Hematol; 2008 Oct; 30(5):390-9. PubMed ID: 19046314
[TBL] [Abstract][Full Text] [Related]
10. Impairment in immuno-modulatory function of Flk1(+)CD31(-)CD34(-) MSCs from MDS-RA patients.
Han Q; Sun Z; Liu L; Chen B; Cao Y; Li K; Zhao RC
Leuk Res; 2007 Nov; 31(11):1469-78. PubMed ID: 17360037
[TBL] [Abstract][Full Text] [Related]
11. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
Kiladjian JJ; Visentin G; Viey E; Chevret S; Eclache V; Stirnemann J; Bourhis JH; Chouaib S; Fenaux P; Caignard A
Haematologica; 2008 Mar; 93(3):381-9. PubMed ID: 18268282
[TBL] [Abstract][Full Text] [Related]
12. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset.
Fozza C; Contini S; Galleu A; Simula MP; Virdis P; Bonfigli S; Longinotti M
Exp Hematol; 2009 Aug; 37(8):947-55. PubMed ID: 19409953
[TBL] [Abstract][Full Text] [Related]
13. Autologous mixed lymphocyte reaction in patients with Hodgkin's disease. Evidence for a T cell defect.
Engleman EG; Benike CJ; Hoppe RT; Kaplan HS; Berberich FR
J Clin Invest; 1980 Jul; 66(1):149-58. PubMed ID: 6447164
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
[TBL] [Abstract][Full Text] [Related]
15. [Cell clonality in myelodysplastic syndrome].
Krejcová H; Neuwirtová R; Cermák J; Belicková M; Brdicka R
Sb Lek; 2002; 103(3):339-48. PubMed ID: 12688178
[TBL] [Abstract][Full Text] [Related]
16. Anti-erythroblast autoimmunity in early myelodysplastic syndromes.
Barcellini W; Zaninoni A; Imperiali FG; Boschetti C; Colombi M; Iurlo A; Zanella A
Haematologica; 2007 Jan; 92(1):19-26. PubMed ID: 17229631
[TBL] [Abstract][Full Text] [Related]
17. [Transcriptome profiling of marrow mononuclear cells of patients with myelodysplastic syndrome using cDNA microarray analysis].
Qian J; Chen ZX; Wang W; Cen JN; Xue YQ
Zhonghua Yi Xue Za Zhi; 2004 Aug; 84(15):1260-4. PubMed ID: 15387962
[TBL] [Abstract][Full Text] [Related]
18. Karyotypic analysis of bone marrow cells in pyodermic lesions associated with myelodysplastic syndrome.
Hamada T; Matsuura H; Oono T; Morizane S; Yamasaki O; Asagoe K; Yamamoto T; Tsuji K; Iwatsuki K
Arch Dermatol; 2008 May; 144(5):643-8. PubMed ID: 18490591
[TBL] [Abstract][Full Text] [Related]
19. [Study of Th cell subsets in bone marrow of myelodysplastic syndromes patients].
Wang XL; Shao ZH; Yao C; He GS; Liu H; Shi J; Bai J; Cao YR; Tu MF; Wang HQ; Xing LM; Sun J; Jia HR; Yang CL
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):743-5. PubMed ID: 16620580
[TBL] [Abstract][Full Text] [Related]
20. The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome.
Metzgeroth G; Rosée PL; Kuhn C; Schultheis B; Dorn-Beineke A; Hehlmann R; Hastka J
Eur J Haematol; 2007 Jul; 79(1):8-16. PubMed ID: 17532764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
